Central Laboratories Featured Articles

1. Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit 1/12/2026

   Opus Genetics CEO George Magrath, MD, discusses how the company introduced virtual reality-enabled assessments and relied on digital endpoints to better measure participants’ vision changes.

2. What Is Win Ratio, And How Can It Be Used In Rare Disease Research? 12/17/2025

   Amber Salzman, CEO of Epicrispr Biotechnologies, explains how applying the win ratio in facioscapulohumeral muscular dystrophy (FSHD) could transform the way researchers evaluate therapeutic impact, enhance statistical efficiency, and improve trial design.

3. Adaptive Trial Design Is Changing Oncology And Hematology Clinical Trials 12/16/2025

   Pfizer Global Development Lead, Clinical Development Oncology & Hematology, Shreya Badhrinarayanan, MD, explains how adaptive trials, enriched by AI and better data integration, are transforming oncology and hematology clinical research.

4. Can't-Miss Advice On Selecting Your First AI-Enabled Vendor 12/12/2025

   Quarles & Brady's Simone Colgan Dunlap and Meghan O’Connor offer actionable guidance to help sponsor companies make informed, strategic choices in an evolving AI market.

5. Why HEOR Keeps Arriving Too Late — And How ClinOps Can Fix It 12/9/2025

   Rob Abbott, CEO of ISPOR, breaks down why HEOR timing keeps clashing with ClinOps timelines and offers practical ways to integrate value, evidence, and payer expectations much earlier in development.

6. Sponsors Collect Too Much "Non-Essential" Data, Say Tufts And TransCelerate 11/6/2025

   A collaboration between Tufts CSDD, Tufts School of Medicine, and TransCelereate BioPharma revealed just how much extra data sponsors are collecting — and why that's a problem.

7. How AI Is Transforming Patient Stratification 10/31/2025

   Discover how AI tools can help stratify or group patients into subtypes that respond differently to treatment.

8. FDA Vs. MHRA Vs. EMA: Differences In Externally Controlled Trials 10/23/2025

   As the FDA, MHRA, and EMA release draft frameworks on externally controlled trials, sponsors face differing expectations. The U.K. leans pragmatic, the U.S. remains cautious, and Europe’s guidance is still evolving — leaving global trial planners to navigate regulatory gray zones.

9. Continuous Evidence Generation — Including RWE — Remains Critical To Vaccine Development 10/23/2025

   President of Takeda's Global Vaccine Business Unit Derek Wallace discusses the importance of continuous, real-world data collection in the context of vaccine development in low- and middle-income countries.

10. What Is Disease Progression Modeling, And When Is The Right Time To Use It? 10/16/2025

    With the help of Clinical Trials Transformation Initiative's Lindsay Kehoe, discover how disease progression modeling can improve trial efficiency, inform precision medicine, assist in regulatory decision-making, and more.